Core Viewpoint - The company is exploring the potential of its subsidiary, Longsheng Tang Pharmaceutical, in Hainan Free Trade Port under the new policy environment [1] Group 1: Company Response - Investors inquired about the potential of Longsheng Tang Pharmaceutical as a development platform under the Hainan Free Trade Port policy [1] - The company confirmed that Longsheng Tang's main products are traditional Chinese medicines, specifically "Qingfei Sanjie Wan" and "Kangai Ping Wan" [1] - The company will continue to support compliant operations and actively explore the functional potential of its products under the Free Trade Port policy [1]